StockData
Becton Dickinson & Co logo

Becton Dickinson & Co (BDX) stock

BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/308% above fair value
$198.34+3.18 (+1.63%)

Close on Oct 29, 2026Market cap $54.03BP/E 59.9Yield 2.10%

Earnings

Becton Dickinson's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$4.98B
Adjusted Diluted Earnings per Share from Continuing Operations, Q3 FY2026
$3.23
Latest guidance
Raised
Aug 6, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Becton Dickinson's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Sep 30, 2026Nov 5, 2026Expected–––––
Q3 FY2026ended Jun 30, 2026Aug 6, 2026before the open$4.98B–$1.37$3.23Release
Q2 FY2026ended Mar 31, 2026Apr 2, 2026during market hours––––Release
Q1 FY2026ended Dec 31, 2025Feb 9, 2026before the open$5.25B+1.0%$1.34$2.91Release
Q4 FY2025ended Sep 30, 2025Nov 6, 2025before the open$5.90B+8.5%$1.72$3.96Release
Q3 FY2025ended Jun 30, 2025Aug 7, 2025before the open––––Release
Q2 FY2025ended Mar 31, 2025May 1, 2025before the open$5.30B+6.0%$1.07$3.35Release
Q1 FY2025ended Dec 31, 2024Feb 5, 2025during market hours$5.20B+10.6%––Release
Q4 FY2024ended Sep 30, 2024Nov 7, 2024before the open$5.44B+6.6%$1.45$3.81Release
Q3 FY2024ended Jun 30, 2024Aug 1, 2024before the open$5.00B+2.0%$1.68$3.50Release
Q2 FY2024ended Mar 31, 2024May 2, 2024before the open$5.00B+4.2%$1.85$3.17Release
Q1 FY2024ended Dec 31, 2023Feb 1, 2024before the open$4.70B+2.2%$0.96$2.68Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Becton Dickinson's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Adjusted Diluted EPSnon-GAAPFY2026$12.62 – $12.72$12.35 – $12.65RaisedAug 6, 2026
Adjusted Diluted EPSnon-GAAPFY2026$14.75 – $15.05–NewNov 6, 2025

Guidance history

Every forecast Becton Dickinson put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Adjusted Diluted EPSFY2026$12.62 – $12.72Raised
Feb 9, 2026Adjusted Diluted EPSFY2026$12.35 – $12.65New
Nov 6, 2025Adjusted Diluted EPSFY2026$14.75 – $15.05New
May 1, 2025Adjusted Diluted EPSFY2025$14.06 – $14.34New
May 1, 2025organic revenue growthFY2025+3% – +3.5%New
May 1, 2025revenuesFY2025$21.80B – $21.90BNew
Feb 5, 2025Adjusted Diluted EPSFY2025$14.30 – $14.60Raised
Nov 7, 2024Adjusted Diluted EPS GrowthFY2025+8.5% – +11%New
Nov 7, 2024Adjusted Diluted EPSFY2025$14.25 – $14.60New
Nov 7, 2024GAAP Revenue GrowthFY2025+8.9% – +9.4%New
Nov 7, 2024Adjusted Revenue Growth (FXN)FY2025+8.8% – +9.3%New
Nov 7, 2024Organic Revenue Growth (FXN)FY2025+4% – +4.5%Lowered
Nov 7, 2024GAAP RevenuesFY2025$21.90B – $22.10BNew
Aug 1, 2024adjusted diluted EPSFY2024$13.05 – $13.15Raised
Aug 1, 2024GAAP revenue growthFY2024+3.7%New
Aug 1, 2024organic revenue growthFY2024+5% – +5.25%Lowered
May 2, 2024Adjusted Diluted EPSFY2024$12.95 – $13.15Raised
May 2, 2024Organic Revenue Growth (FXN)FY2024+5.5% – +6.25%Reaffirmed
May 2, 2024Total RevenuesFY2024$20.10B – $20.30BLowered
Feb 1, 2024adjusted diluted EPSFY2024$12.82 – $13.06Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Becton Dickinson filed with the SEC as exhibits to Form 8-K or 6-K

  1. Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
    Results
  2. Mike Garrison to Retire from BD
    Update
  3. BD Appoints Vitor Roque Chief Financial Officer
    Update
  4. Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
    Results
  5. Rick Byrd to Retire from BD
    Update
  6. Quarterly results release
    Results
  7. Becton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap and Aggregate Offer Cap
    News
  8. Becton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for Purchase
    News
  9. Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
    News
  10. BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
    Update
  11. Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
    Results
  12. New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD.
    Update
  13. Investors: Adam Reiffe, VP, Investor Relations - 201-847-6927
    Results
  14. Investors: Adam Reiffe, VP, Investor Relations - 201-847-6927
    Results
  15. Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
    Results